The ability to genetically engineer plants is largely thanks to a microscopic helper: a bacterium called Agrobacterium ...

Finally, the researchers describe a way to exploit ecDNA’s high rate of replication and transcription: a conflict between DNA ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

Adapted from a news release by the Innovative Genomics Institute (IGI) at UC Berkeley.The ability to genetically engineer plants is largely thanks to ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

Assiduous planning and flexibility were the factors critical to the project’s success. Focusing on these factors enabled us to move at a rapid pace, engage in parallel ramp-up efforts, and devise ...

This transfer occurs via plasmids, which are small pieces of circular DNA separate from the main chromosome. This process happens through physical contact between two bacteria. A "bridge" forms, ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is ...